Halozyme Therapeutics | HALO - Ebitda

Stock Price
65.40
Daily Change
1.80 2.83%
Monthly
-4.02%
Yearly
7.83%
Q2 Forecast
62.55

Halozyme Therapeutics reported $21.9M in EBITDA for its fiscal quarter ending in December of 2025.





Ebitda Change Date
Acadia Pharmaceuticals USD 35.76M 447K Sep/2025
Agios Pharmaceuticals USD -115.49M 10.3M Sep/2025
Alnylam Pharmaceuticals USD 145.22M 236.56M Dec/2025
Amarin USD 12.54M 28.57M Jun/2025
Amgen USD 5.14B 775M Dec/2025
Baxter International USD 426M 36M Sep/2025
Cara Therapeutics USD -2.39M 3.16M Mar/2025
Cytokinetics USD -277.18M 169.36M Sep/2025
DBV Technologies USD -33.48M 5.55M Sep/2025
Eli Lilly USD 7.88B 378.1M Sep/2025
Esperion Therapeutics USD -9.93M 24.99M Sep/2025
Halozyme Therapeutics USD 21.9M 226.34M Dec/2025
Intrexon USD -24.7M 2.92M Jun/2024
Ionis Pharmaceuticals USD -157.12M 307.36M Sep/2025
MannKind USD 17.92M 8.17M Sep/2025
Minerva Neurosciences USD -4.36M 1.71M Sep/2024
Nektar Therapeutics USD -31.81M 70K Sep/2023
Pfizer USD 6.08B 351M Sep/2025
Rigel Pharmaceuticals USD -4.17M 798K Sep/2023
United Therapeutics USD 379.5M 83.4M Dec/2025
Vanda Pharmaceuticals USD -8.31M 2.37M Dec/2024